[1] Day C P, James O F. Steatohepatitis: a tale of two "hits"?[J]. Gastroenterology, 1998,114(4): 842—845.[2] Li X, Wang R, Zhou N, Wang X, Liu Q, Bai Y, Liu Z, Yang H, Zou J, Wang H, Shi T. Quercetin improves insulin resistance and hepatic lipid accumulation in vitro in a NAFLD cell model[J]. Biomed Rep, 2013,1(1): 71—76.[3] Ben M D, Baratta F, Polimeni L, Angelico F. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences[J]. Internal & Emergency Medicine, 2012,7(3): 291—296. [4] 莫志贤,邵红霞. 白藜芦醇苷体外对过氧化氢导致小鼠肝细胞损伤的保护作用[J]. 中国药理学通报, 2000,16(5):519.[5] 万晓强,李孝生,曾庆贵,刘梁英. 大黄酸对TNF-α和TG诱导L-02肝细胞凋亡的影响[J]. 胃肠病学和肝病学杂志, 2006,15(4): 383—386.[6] 李孝生,刘梁英,万晓强. 川芎嗪、大黄酸联用对转化生长因子β1和甘油三酯致肝细胞损伤的影响[C]. 哈尔滨: 中国中西医结合学会第十八次全国消化系统疾病学术会议, 2006.[7] 叶红球. 枳椇子水提取液对乙醇体外诱导肝细胞株LO2细胞损伤的影响[D]. 长沙: 中南大学硕士学位论文, 2012.[8] 黄玉影. 荔枝核有效部位群对实验性非酒精性脂肪肝的治疗作用和机制研究[D]. 广州: 广州中医药大学硕士学位论文, 2016.[9] 岳文杰. 茶叶体外抗氧化效果研究[D]. 福州: 福建农林大学硕士学位论文, 2008.[10] 王丽. 57份茶树种质资源的生化成分及抗氧化活性研究[D]. 福州: 福建农林大学硕士学位论文, 2012.[11] Almajano M P, Carbó R, Jiménez J A L, Gordon M H. Antioxidant and antimicrobial activities of tea infusions[J]. Food Chemistry, 2008,108(1): 5—63. [12] 杨伟丽,肖文军,邓克尼. 加工工艺对不同茶类主要生化成分的影响[J]. 湖南农业大学学报(自然科学版), 2001(5): 384—386.[13] 黄赟. 福建白茶化学成分与感官品质研究初报[D]. 福州: 福建农林大学硕士学位论文, 2013.[14] 张宁. 基于国际标准制定的白茶理化成分的研究[D]. 福州: 福建农林大学硕士学位论文, 2010.[15] 周有良. 萎凋、造型工艺对白茶化学成分含量及品质的影响[D]. 福州: 福建农林大学硕士学位论文, 2010.[16] 潘玉华,高树英,黄先洲,周寒松. 白茶萎凋温度对内含生化成分变化的影响[J]. 蚕桑茶叶通讯, 2013(3): 24—31, 33.[17] 刘淑敏. 不同茶类浸提液及茶多酚的生物活性和机理研究[D]. 广州: 华南理工大学博士学位论文, 2016.[18] Polimeni L, Del B M, Baratta F, Perri L, Albanese F, Pastori D, Violi F, Angelico F. Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis[J]. World Jounal of Hepatol, 2015,7(10): 1325—1336.[19] Albano E. Free radical mechanisms in immune reactions associated with alcoholic liver disease.[J]. Free Radical Biology & Medicine, 2002,32(2): 110—114. [20] Lu K H, Liu C T, Raghu R, Sheen L. Therapeutic Potential of Chinese Herbal Medicines in Alcoholic Liver Disease[J]. Journal of Traditional & Complementary Medicine, 2012,2(2): 115—122.[21] Ding R B, Tian K, Huang L L, He C W, Jiang Y, Wang Y T, Wan J B. Herbal medicines for the prevention of alcoholic liver disease: A review[J]. Journal of Ethnopharmacology, 2012,144(3): 457—465. [22] 叶寅. L-茶氨酸通过增强肝脏细胞中抗氧化物质活性抑制酒精性肝损伤的研究[D]. 南京: 南京大学硕士学位论文, 2011.[23] Koteish A, Diehl A M. Animal models of steatosis.[J]. Seminars in Liver Disease, 2001,21(1): 89—104. [24] Ferré P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c.[J]. Diabetes Obesity & Metabolism, 2010,12(S2): 83—92. [25] Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Masayoshi Y, Yaoa R, Harada N, Takayanagi R, Nakamnta M. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.[J]. International Journal of Molecular Medicine, 2007,20(3): 351—358. [26] Jump D B, Tripathy S, Depner C M. Fatty acid-regulated transcription factors in the liver[J]. Annual Review of Nutrition, 2013,33(1): 249—269.[27] Ahmed M H, Byrne C D. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD)[J]. Drug Discovery Today, 2007,12(17—18): 740—747. |